摘要
目的探讨齐拉西酮和奥氮平对于治疗早期精神分裂症的临床疗效及比较两者的安全性。方法选取我院2017年9月~2019年2月收治的60例早期精神分裂症患者作为研究对象,采用数字随机法将所有患者分成对照组30例和观察组30例,对照组给予奥氮平治疗,观察组给予齐拉西酮治疗。2周为1个疗程,两组均进行8周4个疗程治疗。比较两组患者于治疗前和治疗后2、4、8周进行阳性和阴性症状量表(PANNS)评分,病情严重程度(SI)、疗效总评(GI)评分和不良反应。结果治疗2周、4周后,两组患者的PANSS评分和SI、GI评分均较低于治疗前,但两组的PANSS评分和SI、GI评分比较,差异无统计学意义(P>0.05);疗程结束后,观察组的患者PANSS评分和SI、GI评分均低于对照组,差异有统计学意义(P<0.05);治疗期间,对照组的不良反应发生率高于观察组,差异有统计学意义(P<0.05)。结论对于治疗早期分裂症患者,齐拉西酮的长期治疗效果明显优于奥氮平,且安全可靠,值得临床上进一步推广。
Objective To explore the clinical efficacy of ziprasidone and olanzapine in the treatment of early schizophrenia,and to compare their safety.Methods 60 patients with early schizophrenia admitted and treated in our hospital from September 2017 to February 2019 were selected as the study subjects,and were divided into the control group(30 patients)and the observation group(30 patients)by using the random number method.The control group was treated with olanzapine and the observation group with ziprasidone.2 weeks as a course,and both groups received 4 courses’treatment(8 weeks),the positive and negative syndrome scale(PANNS)scores,severity of illness(SI)and global impression(GI)scores,and adverse reactions were compared between the two groups before treatment and 2,4 and 8 weeks after treatment.Results After 2 weeks and 4 weeks of treatment,PANSS score as well as SI and GI scores of the two groups of patients were all lower than those before treatment,but there was no statistically significant difference in PANSS score as well as SI and GI scores between the two groups(P>0.05);After the course of treatment,PANSS score as well as SI and GI scores of patients in the observation group were all lower than those in the control group,with statistically significant difference(P<0.05);During treatment,the incidence of adverse reactions in the control group was higher than that in the observation group,with statistically significant difference(P<0.05).Conclusion For the treatment of patients with early schizophrenia,ziprasidone is significantly better than olanzapine in terms of long-term therapeutic effect,and is safe and reliable,which is worthy of further clinical promotion.
作者
董勇
杨洪亮
墩雪菲
DONG Yong;YANG Hongliang;DUN Xuefei(Ward 6,Department of Psychiatry,Shenyang Mental Health Center,Shenyang 110168,China)
出处
《中国现代医生》
2020年第11期135-138,共4页
China Modern Doctor
